Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

15.04.2020 | short review | Ausgabe 4/2020 Open Access

memo - Magazine of European Medical Oncology 4/2020

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

memo - Magazine of European Medical Oncology > Ausgabe 4/2020
PhD Dr. Maximilian Marhold, MSc Thaïs Topakian
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Homologous repair deficiency is a clinically relevant molecular aberration in prostate cancer. The goal of this short review is to summarize the study landscape of treatments targeting these aberrations through discussion of the most relevant clinical trials. Due to its shortness, this review does not claim to be exhaustive and a major focus is being laid on PARP inhibitors in clinical development for prostate cancer.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 4/2020

memo - Magazine of European Medical Oncology 4/2020 Zur Ausgabe